Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/45977
Type
ArticleCopyright
Open access
Collections
Metadata
Show full item record28
CITATIONS
28
Total citations
17
Recent citations
3.41
Field Citation Ratio
1.24
Relative Citation Ratio
ARMING MESENCHYMAL STROMAL/STEM CELLS AGAINST CANCER: HAS THE TIME COME?
Câncer
Citocina TWEAK
Terapia genética
Terapia celular
Cancer
Tumor necrosis factor-related apoptosis-inducing ligand,
Gene therapy
Cell therapy
Author
Affilliation
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Department of Medical and Surgical Sciences for Children & Adults. Division of Thoracic Surgery. Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Department of Medical and Surgical Sciences for Children & Adults. Division of Thoracic Surgery. Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Department of Medical and Surgical Sciences for Children & Adults. Division of Plastic Surgery. Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Department of Medical and Surgical Sciences for Children & Adults. Division of Plastic Surgery. Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Health Institute of Technology. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Health Institute of Technology. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Health Institute of Technology. Salvador, BA, Brasil.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy / Rigenerand srl,.Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy / Rigenerand srl,.Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Department of Medical and Surgical Sciences for Children & Adults. Division of Thoracic Surgery. Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Department of Medical and Surgical Sciences for Children & Adults. Division of Thoracic Surgery. Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Department of Medical and Surgical Sciences for Children & Adults. Division of Plastic Surgery. Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Department of Medical and Surgical Sciences for Children & Adults. Division of Plastic Surgery. Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Health Institute of Technology. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Health Institute of Technology. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Health Institute of Technology. Salvador, BA, Brasil.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy / Rigenerand srl,.Modena, Italy.
University-Hospital of Modena and Reggio Emilia. Laboratory of Cellular Therapy. Department of Medical and Surgical Sciences for Children & Adults. Division of Oncology, Modena, Italy / Rigenerand srl,.Modena, Italy.
Abstract
Since mesenchymal stromal/stem cells (MSCs) were discovered, researchers have been drawn to study their peculiar biological features, including their immune privileged status and their capacity to selectively migrate into inflammatory areas, including tumors. These properties make MSCs promising cellular vehicles for the delivery of therapeutic molecules in the clinical setting. In recent decades, the engineering of MSCs into biological vehicles carrying anticancer compounds has been achieved in different ways, including the loading of MSCs with chemotherapeutics or drug functionalized nanoparticles (NPs), genetic modifications to force the production of anticancer proteins, and the use of oncolytic viruses. Recently, it has been demonstrated that wild-type and engineered MSCs can release extracellular vesicles (EVs) that contain therapeutic agents. Despite the enthusiasm for MSCs as cyto-pharmaceutical agents, many challenges, including controlling the fate of MSCs after administration, must still be considered. Preclinical results demonstrated that MSCs accumulate in lung, liver, and spleen, which could prevent their engraftment into tumor sites. For this reason, physical, physiological, and biological methods have been implemented to increase MSC concentration in the target tumors. Currently, there are more than 900 registered clinical trials using MSCs. Only a small fraction of these are investigating MSC-based therapies for cancer, but the number of these clinical trials is expected to increase as technology and our understanding of MSCs improve. This review will summarize MSC-based antitumor therapies to generate an increasing awareness of their potential and limits to accelerate their clinical translation.
Keywords in Portuguese
Células-Tronco MesenquimaisCâncer
Citocina TWEAK
Terapia genética
Terapia celular
Keywords
Mesenchymal stromal/stem cellCancer
Tumor necrosis factor-related apoptosis-inducing ligand,
Gene therapy
Cell therapy
Share